A BILL 
To amend the Federal Food, Drug, and Cosmetic Act to 
clarify reporting requirements for establishments within 
a foreign country engaged in the manufacture, prepara-
tion, propagation, compounding, or processing of an ac-
tive pharmaceutical ingredient, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Improved Trans-
4
parency of Foreign Drug Manufacturing Act of 2022’’. 
5
02:16 Jan 26, 2022
H6483
2 
•HR 6483 IH
SEC. 2. REPORTING REQUIREMENT FOR DRUG MANUFAC-
1
TURERS. 
2
(a) ESTABLISHMENTS IN A FOREIGN COUNTRY.— 
3
Section 510(i) of the Federal Food, Drug, and Cosmetic 
4
Act (21 U.S.C. 360(i)) is amended by inserting at the end 
5
the following: 
6
‘‘(5) The requirements of paragraphs (1) and 
7
(2) shall apply to establishments within a foreign 
8
country engaged in the manufacture, preparation, 
9
propagation, compounding, or processing of any 
10
drug, including the active pharmaceutical ingredient, 
11
that is required to be listed pursuant to subsection 
12
(j). Such requirements shall apply regardless of 
13
whether the drug or active pharmaceutical ingre-
14
dient undergoes further manufacture, preparation, 
15
propagation, compounding, or processing at a sepa-
16
rate establishment or establishments outside the 
17
United States prior to being imported or offered for 
18
import into the United States.’’. 
19
(b) LISTING OF DRUGS.—Section 510(j)(1) of the 
20
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
21
360(j)(1)) is amended— 
22
(1) in subparagraph (D), by striking ‘‘and’’ at 
23
the end; 
24
(2) in subparagraph (E), by striking the period 
25
at the end and inserting ‘‘; and’’; and 
26
02:16 Jan 26, 2022
H6483
3 
•HR 6483 IH
(3) by adding at the end the following: 
1
‘‘(F) in the case of a drug contained in the 
2
applicable list, a certification that the registrant 
3
has— 
4
‘‘(i) identified every other known es-
5
tablishment where manufacturing is per-
6
formed for the drug; and 
7
‘‘(ii) notified each known foreign es-
8
tablishment engaged in the manufacture, 
9
preparation, propagation, compounding, or 
10
processing of the drug, including the active 
11
pharmaceutical ingredient, of the inclusion 
12
of the drug in the list and the obligation 
13
to register.’’. 
14
(c) QUARTERLY REPORTING ON AMOUNT OF DRUGS 
15
MANUFACTURED.—Section 510(j)(3)(A) of the Federal 
16
Food, Drug, and Cosmetic Act (as added by section 3112 
17
of the CARES Act (Public Law 116–136)) is amended 
18
by striking ‘‘annually’’ and inserting ‘‘once during the 
19
month of March of each year, once during the month of 
20
June of each year, once during the month of September 
21
of each year, and once during the month of December of 
22
each year’’. 
23
Æ 
02:16 Jan 26, 2022
H6483
